Nine new members join the European Medicinal Cannabis Association

“Only by coming together and acting as a collective can we make real change. This is why we are urging other organisations, both large and small, to join the EUMCA as we look to promote scientific medical research, and to bring a credible voice that drives and shapes policy in the standardised, ethical and sustainable use of medicinal cannabis across the region.”

Says Sita Schubert, General Secretary of the European Medicinal Cannabis Association 

_______________________________________________________________________________

Brussels, 9 January 2020: The European Medicinal Cannabis Association (EUMCA), the newly formed Brussels-based industry body who advocate for the advancement of European evidence-based policy to improve patient access to high-quality cannabis treatment, has today welcomed nine members to the association. Founding members include: Bundesverband der PharmazeutischenIndustrie (BPI), Cannaflos, Comm-Op Europe,Ethical Medicines Industry Group (EMIG), Iqanna, Materia Ventures, MSSV, Panaxia and Tilray,

The EUMCA,Incorporated on 14th November 2019, represents the interests of ethical companies working in the supply and manufacturer of medicinal cannabis. It’s aim is to create a supportive and harmonised EU regulatory environment in which producers and manufacturers sign up to good manufacturing practices (GMP) and deliver medicinal cannabinoid treatments that conform with acknowledged scientific standards of quality, safety and efficacy.

Sita Schubert, General Secretary of the European Medicinal Cannabis Association, commented:

“We are delighted to have these highly regarded manufactures, suppliers and organisations join the EUMCA as we look to create a standardised and harmonised regulatory prescribing framework to which all Member States can confidently ascribe.

“However, this will not be achieved in the absence of a base of sound scientific evidence, which is reliant on ethical producers and manufacturers of medicinal cannabinoid treatments signing up to good manufacturing practices (GMP).


“Our founding members represent organisations that have already advanced our scientific knowledge and understanding in this field. Only one in 300,000 patients across Europe are able to access medical cannabis-based treatments, and we at the EUMCA do not think that is fair. Only by coming together and acting as a collective can we make real change. This is why we are urging other organisations, both large and small, to join the EUMCA as we look to promote scientific medical research, and to bring a credible voice that drives and shapes policy in the standardised, ethical and sustainable use of medicinal cannabis across the region.”

For further information, please contact:

SENSO Communications
Penny Lukats, 07775992350, penny@sensocommunications.com

For more information on the EUMCA (www.eumca.org)and membership, please contact:
Sita Schubert, General Secretary of the EUMCA on+32 233 90 281, info@eumca.org

 

NOTES TO EDITORS

The EUMCA is the first international non-profit association governed by the provisions of the Belgian Code des Sociétés et des Associations. Its membership is a multi-stakeholder network representing the interests of a wide range of organisations operating in the research and development, production and/or distribution of medical cannabis-based treatments.

The EUMCA’s mission is to improve the life and health outcomes of patients across Europe, by promoting the development of national government healthcare policies that advocate i) the ethical prescription of pharmaceutical-grade medicinal cannabis, and ii) advance patient access to treatments. It does this through:

  • Research & Development: Promoting scientific medical research and policy to support the standardised, ethical and sustainable use of medicinal cannabis.
  • Patient Access & Reimbursement: Working with national reimbursement institutions to improve patient access to medical cannabis-based treatments.
  • Medical Education: Providing evidence-based knowledge and learning on medicinal cannabis to healthcare professionals and patients.
  • Legal & Compliance: Consulting with governments where ongoing or urgent action is necessary.
  • Regulatory & Quality: Providing members with counsel and guidance on regulatory affairs.
  • Business Development: Delivering networking opportunities for members focused on building their business through M&A, licensing, partnering and novel in-market strategies.
WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly